biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Midatech's Glioblastoma Drug and xB3 Synergy:

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jan 15, 2023 5:52pm

87 Views

Post# 35224485

RE:RE:RE:Midatech's Glioblastoma Drug and xB3 Synergy:

Ohhhhhhhhhhhhh, I didn't realize that Midatech had a better brain delivery technology than xB3. I thought i read that Stephen Stamp was happy to get xB3.

Well, I guess Bioasis was wrong in that 2017 quote.

So, why, exactly, did you copy/paste it?

jd

<< Previous

Bullboard Posts

Next >>

Futures Flat Amid Key Data in Canada and US